Tag: GW Pharma

GW Pharma Reports FY17-Q1 Financials

GW Pharmaceuticals plc Reports First Quarter 2017 Financial Results and Operational Progress Epidiolex® NDA submission and launch preparation on track New Positive Phase 2 glioma data further demonstrates value...
- February 7th, 2017 at 8:44 am

GW Pharma Ends FY16 with $483mm in Cash

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2016 Financial Results and Operational Progress – Three Positive Phase 3 Epidiolex clinical trials reported in 2016 – – NDA submission...
- December 5th, 2016 at 7:52 am

GW Pharma Progresses Towards Epidiolex FDA Submission

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome – Posters Presented at American Epilepsy Society Annual Meeting – – New data includes...
- December 5th, 2016 at 7:39 am

Risk Rises for U.S. Cannabis Penny Stocks

The publicly-traded cannabis stocks have enjoyed an immense rally that began on 9/1, fueled by speculation regarding this week’s legalization ballot initiatives in Arizona, California, Maine, Massachusetts and Nevada along with...
- November 6th, 2016 at 12:08 am

GW Pharma to Drop Dual Listing and Trade Only on NASDAQ

GW Pharmaceuticals plc Announces Intention to Continue Trading Exclusively on NASDAQ and Planned Cancellation of Trading of Ordinary Shares on AIM GW remains headquartered in UK and continues to...
- October 19th, 2016 at 4:42 am

GW Pharma Soars on Takeover Rumors

Shares in GW Pharma (NASDAQ: GWPH) (AIM: GWP) shot up in trading today after Reuters posted an exclusive report that the company has hired investment bank Morgan Stanley in...
- September 7th, 2016 at 3:47 pm

GW Pharma Closes $290mm Stock Sale

GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriter’s Option...
- July 18th, 2016 at 11:30 am

GW Pharma to Raise up to $172.5mm

GW Pharmaceuticals Announces Proposed Public Offering of ADSs LONDON, July 12, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing...
- July 12th, 2016 at 4:13 pm

GW Pharma Epidiolex Gains 4th Orphan Drug Designation

GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS) – Orphan Drug Designation Granted from FDA for Epidiolex for the Treatment of IS...
- June 21st, 2016 at 9:44 am